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Abstract
Background: The optimal criteria to diagnose gestational diabetes mellitus (GDM) remain contested. The Swedish
National Board of Health introduced the 2013 WHO criteria in 2015 as a recommendation for initiation of treatment
for hyperglycaemia during pregnancy. With variation in GDM screening and diagnostic practice across the country,
it was agreed that the shift to new guidelines should be in a scientific and structured way. The aim of the Changing
Diagnostic Criteria for Gestational Diabetes (CDC4G) in Sweden (www.cdc4g.se/en) is to evaluate the clinical and
health economic impacts of changing diagnostic criteria for GDM in Sweden and to create a prospective cohort to
compare the many long-term outcomes in mother and baby under the old and new diagnostic approaches.
Methods: This is a stepped wedge cluster randomised controlled trial, comparing pregnancy outcomes before and
after the switch in GDM criteria across 11 centres in a randomised manner. The trial includes all pregnant women
screened for GDM across the participating centres during January–December 2018, approximately two thirds of all
pregnancies in Sweden in a year. Women with pre-existing diabetes will be excluded. Data will be collected through
the national Swedish Pregnancy register and for follow up studies other health registers will be included.
Discussion: The stepped wedge RCT was chosen to be the best study design for evaluating the shift from old to new
diagnostic criteria of GDM in Sweden. The national quality registers provide data on the whole pregnant population
and gives a possibility for follow up studies of both mother and child. The health economic analysis from the study will
give a solid evidence base for future changes in order to improve immediate pregnancy, as well as long term,
outcomes for mother and child.
Trial registration: CDC4G is listed on the ISRCTN registry with study ID ISRCTN41918550 (15/12/2017)
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Background
Hyperglycaemia during pregnancy is a growing problem
globally and is associated with several long- and short-term
adverse outcomes for the mother and offspring [1–5]. In
particular, maternal hyperglycaemia induces foetal hyperin-
sulinemia with enhanced foetal growth and increased risk
of foetuses being born large for gestational age (LGA). The
rate of macrosomia, neonatal hypoglycaemia and caesarean
delivery increase linearly with increasing levels of maternal
hyperglycaemia [6]. Women with GDM are also at higher
risk of gestational hypertension and preeclampsia. In the
long term, metabolic diseases such as Type 2 diabetes mel-
litus (T2DM), cardiovascular disease and obesity are more
frequent among women with prior GDM [2, 7–9] . In off-
spring GDM has been shown to be associated with adipos-
ity and risk for prediabetes [3, 4, 10, 11]. Treatment of
GDM involves dietary and physical activity advice, blood
glucose monitoring, and where necessary metformin or/
and insulin therapy. GDM management has been shown to
reduce maternal and perinatal morbidity [12–14].
Internationally, the prevalence of GDM varies from 1 to
28% depending on the ethnic composition and prevalence
of T2DM of the background population, local GDM
screening strategies and diagnostic criteria [15–17]. This
variation in screening and diagnostic approaches has made
global comparisons of GDM prevalence and outcomes
problematic. In order to progress towards a universal
standard approach to GDM diagnosis, the World Health
Organisation (WHO) recommended in 2013 that a 2-h
75 g oral glucose tolerance test (OGTT) should be used,
with three time points blood testing (fasting, 1- and 2-h)
[1]. These 2013 WHO criteria define GDM as ≥5.1, ≥10.0
and/or ≥ 8.5mmol/L fasting, 1-h and/or 2-h thresholds.
These cut-off values are based on a ≥ 75% adjusted excess
risk of adverse neonatal outcomes (e.g. large for gesta-
tional age (LGA), foetal hyperinsulinemia), based on data
from the Hyperglycaemia and Adverse Pregnancy Out-
comes (HAPO) study involving 25,505 women from nine
countries [18]. There has been debate over the merits of
these new criteria as the number of women diagnosed
with GDM would be expected to increase by 15–30%,
raising concerns over their cost and clinical effectiveness
[19–22]. While the thresholds are based upon calculated
excess risk, the decision to base the diagnostic criteria on
≥75% excess risk was based upon consensus. Some coun-
tries (e.g. Canada, Norway) have reduced GDM numbers
by using thresholds based upon a ≥ 100% excess risk of
adverse neonatal outcomes (5.3- and/or 10.6- and/or 9.0
mmol/L, respectively) [23, 24]. Others have not based
their criteria on HAPO data at all (e.g. England, New
Zealand).
Older Swedish GDM criteria are based on varying cut-
off values. If a fasting threshold was used (not used in one
region), then ≥7.0 mmol/L was considered GDM. The 2 h
criteria ranged from 9.0–11.1mmol/L, using either capil-
lary or venous samples. Using these criteria, 1–3% of the
115, 000 births were complicated by GDM annually. In
June 2015, following a review of the available evidence, the
Swedish National Board of Health and Welfare (SNBHW)
recommended a move to the 2013 WHO diagnostic cri-
teria, using venous sampling. The SNBHW made no rec-
ommendations in relation to the screening (e.g. universal
vs risk factor).
With the current variation in GDM screening/diagnos-
tic practice across Sweden [25], and the debate over the
criteria, there was a recognition that the transition to the
recommended new guidelines could be either by an ad
hoc, or planned and structured way, to minimise clinical
variation. National registers in Sweden offer a possibility
to assess the impact of introducing the new GDM cri-
teria on pregnancy outcomes and long-term health for
both mother and child. A stepped wedge cluster rando-
mised controlled trial (SW-CRCT) was the most realistic
approach to evaluate this change on a national level
[26–30]. A SW-CRCT involves randomly allocated times
for clusters to introduce an intervention, allowing partic-
ipants before and after any change to serve as control
and intervention groups respectively. Reasons for choos-
ing this study design were:
1. The intervention is a change in one clinical routine
in a population, making it unrealistic to randomise
by individual.
2. All sites were to end with adopting the national
guidelines as promptly as possible, which would have
been delayed using a simple case control approach.
3. Roll out in one go, across multiple centres was
unrealistic, making a parallel cluster randomised
controlled trial unrealistic. Steady adoption, site by
site, was seen as the best way to make the change
in the most organised manner.
This study will provide evidence to help address some
of the clinical controversies over GDM diagnosis. Our
aim is to test whether there is a reduction in adverse
neonatal and maternal outcomes following the imple-
mentation of the new GDM criteria, and to evaluate the
health economic impact on a population level.
Our specific objectives are:
1. To compare the rates of LGA and other adverse
neonatal and maternal pregnancy outcomes before
and after the change in GDM diagnostic criteria.
2. To compare the health care costs before and after
the change and assess the net costs/savings.
3. To create prospective cohorts to compare the long-
term outcomes in mothers and offspring exposed to
the old and new diagnostic approaches.
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Methods
Study design
The Changing Diagnostic Criteria for Gestational dia-
betes (CDC4G) in Sweden study is a national prospect-
ive, unblinded, SW-CRCT of the switch from the
former Swedish diagnostic criteria to the WHO 2013
criteria for GDM i.e. to the 3 point OGTT with fasting
plasma glucose, 1-h and/or 2-h diagnostic thresholds of
≥5.1, ≥10.0, ≥8.5 mmol/L, respectively (Fig. 1). Each
participating centre constitutes one cluster, in which
the patients continue to undergo screening for GDM
following their usual approach, see Table 1. The time
of transition to the new criteria is randomised and sub-
sequently rolled out until all 11 clusters (i.e. centres)
implement the new GDM regimes during 2018, see
Fig. 2. The transition necessitated the introduction of a
fasting glucose sample in one region, and a 1-h sample
across all 11 regions. This means that a total population
evaluation of the change is required, as many women
with GDM diagnosed by the new criteria, will not be
identified during the control period (e.g. those without
the 1-h test). A sub-analysis among those with un-
treated and treated GDM by the WHO 2013 is also
planned.
Sites have previously varied in how samples were
taken, with some using capillary and some venous sam-
pling. As venous sampling was used in the HAPO study,
and is the approach recommended by the SNBHW and
the WHO, all study centres using capillary sampling for
diagnosing GDM changed to venous during the national
preparation period (September–December 2017). GDM
clinical management has also varied across the country
and new guidelines for GDM treatment and obstetric
surveillance were introduced during the national prepar-
ation period, prior to the commencement of the trial. It
was agreed that no local policy should change over the
trial period.
The trial was performed within the Swedish Network
for Clinical Studies within Obstetrics and Gynaecology
(SNAKS; www.sfog.se).
Fig. 1 Time of preparation, set up, control and intervention in the CDC4G study during 2017, 2018 and 2019. Q = quartile, 3 months period
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Participants
All regions in Sweden were invited to participate over
the 12-month study period. Eleven (65–67,000 birth/
year) out of 21 regions in Sweden agreed to participate.
All women within the participating regions (including
within both primary and secondary care) across Sweden
are included in the study, unless they opt out from the
national register. Women with pre-existing diabetes are
excluded. This approach, to use de-identified data from
the national registers, without individual consent, was
approved by the Uppsala Regional Ethics committee on
behalf of all Research Committees across Sweden. The
Table 1 List of included regions and methods for diagnosing GDM
Centres Number
of births
2017a
Indication for a diagnostic OGTT Diagnostic
criteria
prior to
switch
(mmol/L)
Method for
glucose analysisPrevious BMI at
booking
FHd Polyhyd
ramnios
Accelerated
fetal growth
RPG
GDM Macro
somiab
LGAc Stillbirth
1.
Stockholm
28,602 T1 &
24–
28
24–28 ≥35 Yes Yes RPGe≥ 9 mmol/L at
booking, week 25,
29, 32/33, 37/38.
FPG < 7.0
and
2-h PG
8.9–11.1
Roche Cobas
Beckman
Coulter Au.
Siemens Advia
(hexokinase)
2. Örebro 3565 24–
28
24–28 ≥35 24–
28
Yes Yes-within
3 days
RPGe≥ 9 mmol/L at
booking, week 24,
28/29, 33, 37.
FPG < 7.0
and
2-h PG
8.9–11.0
Siemens Advia
(hexokinase)
3.
Västmanland
3120 24–
28
24–28 > 35 Yes Yes RPGe≥ 9.0 mmol/L
at booking week
25, 30, 35.
FPG < 7.0
and
2-h PG
8.9–11.
Beckman
Coulter Au
(hexokinase)
4. Dalarna 3232 12–
14/
24–
28
24–28 24–28 > 35 24–
28
Yes Yes RPGe≥ 9.0 mmol/L
at booking, week
24, 28/29, 33, 37.
FPG < 7.0
and/or
2-h PG
8.9–11.1
Siemens Advia
(hexokinase)
5. Uppsala 4200 12–
14/
24–
28
24–28 24–28 ≥35 24–
28
Yes Yes RPGe≥ 8.8 mmol/L
at booking, week
25, 28/29, 33, 37
FPG ≥7.0
and/or 2-h
PG ≥10.0
Abbott
Architect
(hexokinase)
6. Göteborg 9550 25–
29
25–29 25–29 ≥35 25–
29
Yes (Yes) Within 1 week if
RPGe 8.0–12.1
mmol/L at first
antenatal care visit,
week 25, 28–29,
35–36.
FPG ≥7.0
and/or 2-h
PG ≥10.0
RPGc≥
12.2
Nova
Biomedical
StatStrip TM
Multi-Well™
(glucose
oxidase)
7. Gotland 538 24–
28
24–28 24–28 ≥35 24–
28
Yes Yes RPGe≥ 9.0 mmol/L
at enrollment week
25, 29, 32/33, 37/
38.
FPG < 7.0
and 2-h
PG 8.9–
11.0
HemoCue AB
HemoCue 201
RT (glucose
dehydrogenase)
8. Halland 4446 12/
24–
28
24–28 24–28 ≥30 24–
28
Yes Yes RPGe≥ 8.0 mmol/L
at enrollment,
week 12, 28/29, 32,
37
FPG < 7.0
and 2-h
PG 9.0–
11.1
HemoCue AB
HemoCue 201
RT (glucose
dehydrogenase)
9. Malmö 4944 10–
12
10–12 ≥35 10–
12
Yes No Capillary 75 g OGTT
week 28 in all
women.
FPGe≥ 7 and/or 2-
h PGe ≥ 10.0 mmol/
L indication for a
diagnostic OGTT
FPG ≥7.0
and/or
2-h PG
≥9.0
Roche Cobas
(hexokinase)
10. Lund 3703 10–
12
10–12 ≥35 10–
12
Yes No
11.
Kristianstad
2085 10–
12
10–12 ≥35 10–
12
Yes No
Legend: When not otherwise stated, glucose measurement is based on venous plasma
BMI body mass index, FH family history, FPG fasting plasma glucose, IUFD intrauterine fetal death, LGA large for gestational age, OGTT oral glucose tolerance test,
PG plasma glucose, RPG random plasma glucose, T1 trimester 1
aNumber of births per year based on data from the Swedish Medical Birth register year 2017
bDefined as birth weight ≥ 4.5 kg
cDefined as birth weight ≥ + 2 standard deviations above the Swedish reference curve [31]
dIn Dalarna, Malmö, Lund, Kristianstad, Uppsala, Gotland, Halland defined as first degree relative with type 1 or type 2 diabetes, otherwise first degree relative
with type 2 diabetes
eBased on capillary samples
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national SPR uses an opt out approach, with less than
100 opts out yearly.
Outcomes
The primary outcome is LGA (birth weight above the
90th percentile for gestational age and sex using centile
tables) based on Swedish reference population (twins,
major malformations and intrauterine deaths excluded
from reference population). This is the only common
pregnancy outcome shown to be substantially and con-
sistently reduced by treating GDM [32].
Secondary outcomes for neonate and mother are listed
in Table 2.
A healthcare cost-utility analysis will be undertaken.
Recruitment
Women will be recruited de facto by being under the
care of a participating health service. Women always
have an option to decline testing and, if GDM is diag-
nosed, to decline treatment. Informed consent will not
be requested beyond the routine invitation to opt out of
the SPR and the option at any time to refuse any aspect
of management.
Randomisation
As the expected number of births varies across the par-
ticipating centres, a stratified randomisation by centre
size was conducted using two strata. The first strata was
the two largest populated study centres (Stockholm and
Gothenburg) which was randomised to change GDM
criteria in June or August of 2018. The second strata
with the nine remaining centres was changing, one
centre per month, in a randomised order from February
to July and September to November of 2018. The ran-
domisation allocation was performed using computer-
generated, random allocation sequences using SPSS
version 22 (Armonk, NY:IBM Corp) by the study statisti-
cian at Clinical Epidemiology and Biostatistics, Region
Örebro County. The randomisation was concealed from
the participating centre and the list is stored in a safe at
Örebro University Hospital.
The study statistician provided information on the
randomisation to the study coordinator who in turn
informed the relevant centre through the local PI, 2
months prior to when the centre being randomised to
using the new GDM criteria. Staff at all sites were
blinded until informed by their local PI of their start
date to change from the control period (old GDM cri-
teria) to the intervention period (new GDM criteria).
Monitoring of adhesion to the study protocol
Every month each centre reported their monitoring
according to a checklist on the website (ref according to
guidelines) to make sure that the guidelines for the
CDC4G study (e.g. GDM treatment, blood sampling
methods, obstetric surveillance, switch to the new cri-
teria) were followed every step of the study. In addition,
the number of women with GDM diagnosed every
month during the study period is registered. Severe pos-
sible adverse outcomes such as (severe maternal
hypoglycaemia (low blood glucose levels that requires
assistance from another person to treat) and lactic acid-
osis in metformin treated women) is reported each
month. Interim analysis is performed by the study co-
ordinator every month to identify any safety or protocol
breaches. The study data and safety monitoring board
(DSMB) is available to determine whether any safety is-
sues warranted termination of the trial.
Procedures
A 3-month national preparation period was organized
between October to December 2017 (Fig. 2), for all sites
to consolidate their local approach to screening, chan-
ging diagnostic testing to venous sampling, modifying
and consolidating the agreed approach to GDM treat-
ment and the agreed approach to obstetric management.
The trial started on the 1st of January 2018 with 1
month of baseline data collection when no randomisation
Site 
number
Time of preparation, control and intervention
11
10
9
8
7
6
5
4
3
2
1
Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3
2017 2018 2019
National preparation period Control period Intervention period
Fig. 2 CONSORT 2010 flow diagram of the stepped wedge cluster randomised CDC4G - trial
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Table 2 Outcomes, sampling and measurements
Data collection points
Method Sources Baseline During
pregnancy
Birth/
postpartum
Primary Outcome
LGAa scale SPRb x
Secondary maternal outcomes
Gestational Hypertension Blood pressure or ICD code SPRb/ eCRFf x x
Pre-eclampsia ICD code SPRb x x
Shoulder dystocia ICD code SPRb x
Induction of labour ICD code SPRb x
Emergency LSCS ICD code SPRb x
Elective LSCS ICD code SPRb x
Instrumental delivery ICD code SPRb x
Length of maternal stay from delivery
to discharge
hours, days SPRb x
Perineal trauma-3 and 4 degree ICD code SPRb x
Breastfeeding at hospital discharge Yes/no SPRb x
Maternal HbA1c (mmol/mol) Blood sample eCRFf x x
Self-reported health Scale 1–6 SPRb x x
Satisfaction with childbirth Scale 1–10 SPRb x
Post-part bleeding ml SPRb x
Gestational weight gain g or kg SPRb x x
Secondary neonatal outcomes
Stillbirth (≥22 + 0) ICD code SPRb/SNQc x
Neonatal death (< 28 days) ICD code SPRb /SCBd x
Erbs palsy ICD code SPRb/SNQc x
Metabolic acidosisg Umbilical artery and venous
blood sample
SPRb x
1,5,10 min Apgar score < 4 Clinical examination SPRb x
Hypoxic ischemic encephalopathy I-III ICD code SPRb/SNQe x
Intracranial haemorrhage ICD code SPRb/SNQe x
Meconium aspiration syndrome ICD code SPRb/SNQe x
Mechanical ventilation SPRb/SNQe x
Fractured clavicle/humerus ICD code SPRb/SNQe x
Blood glucose in the infants (mmol/L) Blood sample eCFRf x
Preterm birth < 37, 34 or 32 weeks ICD code SPRb x
NICU date (xxxx/yy/zz) eCRFf x
NICU days days eCRFf/SPRb x
SGAh Calculated from birth weight /
gestational age/gender
SPRb x
Bilirubin (highest value) Blood sample eCRFf x
Phototherapy Medical record eCRFf
Hypoglycaemia needing IV therapy eCRFf x
Supplementary feeding
Supplementary feeding indication Medical record eCFRf x
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occurred. Subsequently, at periodic time points called
“steps”, sites changed to the new GDM criteria in a rando-
mised order over a 10months period. In December 2018
all sites used the new criteria. The last birth is expected in
August 2019.
Booking screening Booking screening varied between
the centres. In some centres, high risk women under-
went an OGTT, other centres used universal random
blood glucose screening to identify those for referral to
OGTT, see Table 1. The OGTT thresholds used for
overt diabetes in pregnancy are listed in Table 1.
The oral glucose tolerance test (OGTT) Throughout
the study period, a 2-h 75 g OGTT was undertaken fol-
lowing booking screening, at 24–29 weeks gestation or if
there was a clinical indication (e.g. polyhydramnios, ac-
celerated growth or high random blood glucose).
Venous sampling were used with glucose measure-
ments performed either by the local laboratory or with
point of care testing (Table 1). All the laboratories are
accredited according to SS-EN-ISO/IEC 15189. As part
of the accreditation the laboratories participate in inter-
laboratory comparison schemes either from Equalis
(https://www.equalis.se/en/) or in schemes organised by
the local hospital organisation.
GDM management guidelines GDM management
(treatment and obstetrical surveillance) was the same in
all centres before and after the switch. All women re-
ceived a GDM information leaflet and written dietary
advice in Swedish and translated into five other lan-
guages (English, Pashto, Somali, Arabic and Dari). All
women diagnosed with GDM were offered lifestyle ad-
vice from a registered dietitian. Further general GDM in-
formation was provided by the midwife if lifestyle
treated, and the diabetes team if treated with insulin or
metformin. A local diabetes nurse or trained midwife
taught women on how to undertake self-measurement
of plasma glucose (SMPG). Different meters were used,
but all were capable of uploading data through DIA-
SEND® (Glooko AB, Göteborg, Sweden) which is consid-
ered to be part of the local clinical records. SMPG was
recommended to occur four times per day: Fasting and
1 h after breakfast, lunch and dinner among those who
are lifestyle treated and seven times per day among those
treated with insulin and/or metformin (before and 1 h
after meals and at night before bed).
Target values for capillary plasma glucose were < 5.3
mmol/L fasting (before breakfast), < 6.0 mmol/L before
other meals, < 8.0 mmol/L 1 h after meals, and < 7.0
mmol/L before bedtime. Those with three or more
values above target during 1 week were commenced on
pharmacological treatment or intensified treatment if
already on metformin/insulin. GDM management (treat-
ment and obstetrical surveillance) was the same in all
centres before and after the switch.
Pharmacological treatment
Metformin is accepted for treatment of GDM by the
Swedish National Board of Health (https://www.socialstyr
elsen.se/globalassets/sharepoint-dokument/artikelkatalog/
nationella-riktlinjer/2015-4-12.pdf) and it is used mainly
for overweight patients (BMI ≥ 25 kg/m2), especially where
fasting glucose and basal glucose levels were elevated dur-
ing the day. Written and oral information was provided
regarding adverse effects and that metformin crosses the
placenta. Start dose was 500mg once daily, with increas-
ing one tablet every third day until target glucose level
was achieved.
Insulin is recommended when metformin is not ex-
pected to bring hyperglycaemia rapidly under control, or
when considered inappropriate for clinical reasons or
declined by the patient. If fasting blood glucose is above
Table 2 Outcomes, sampling and measurements (Continued)
Data collection points
Method Sources Baseline During
pregnancy
Birth/
postpartum
Interval (hours) and volume (ml) of supplementary feeding eCFRf x
Product used eCFRf x
Use of dextrose gel or intravenous
treatment
eCFRf x
a Large for Gestational Age: Birth weight above the 90th percentile for gestational age in the Swedish reference population corrected for gestational age
and gender
b Swedish pregnancy register: Diagnosis based on ICD codes or values (ml, kg, g, numbers). Variable list available on https://www.medscinet.com/gr/forskare.aspx
c The Swedish National Patient Register
d Statistics Sweden
e Swedish Neonatal Quality Register
f eCFR.www.medscinet.com
g pH < 7.05 and BE > 12mmol/L or pH < 7.0
h Birth weight < 10th percentile for gestational age, corrected for gestational age and gender. Swedish reference population
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the target, intermediate acting insulin (NPH) is the first
line of choice. Long acting analogue insulins are consid-
ered if the blood glucose targets are not reached. Rapid
acting insulin analogues are used to manage elevated
postprandial glucose levels. Evaluation of glucose values
and titration of insulin dose are recommended twice a
week initially, after which titration is performed once a
week. Changes in insulin doses occurred if three or four
values are above the target value over a 1-week period.
Starting doses are 4–8 units depending on the glycaemia
and other clinical factors (e.g. BMI).
Obstetric surveillance
All women with GDM receive written information about
health and exercise and continue with the usual obstetric/
midwifery care including additional intervention when in-
dicated. Women with diagnosed GDM and lifestyle man-
agement alone received expectant care as per normal
pregnancy management with foetal weight estimation at
week 38 for pre-delivery assessment. For women receiving
metformin or insulin treatment, additional ultrasound as-
sessments for foetal weight estimation was performed at
least 2 times during pregnancy: at weeks 28–32 and latest
at 38 weeks. Induction occurs if not delivered before 40 +
6 for medically treated GDM women, and for diet treated
GDM induction at the latest 42 + 0.
Data collection
Data will be collected through the SPR, a national qual-
ity registry [33]. An additional electronic case record
form is created with manually entered data not other-
wise collected in the SPR (e.g. neonatal blood glucose
and repeat OGTT values). Follow up studies will use the
National Diabetes Register (NDR) and other Swedish
health care registers (SNQ, Prescribed Drug register, Sta-
tistics Sweden). Glucose monitoring and target adher-
ence were collected through the use of DIASEND®.
First data set extraction is planned to be completed
during 2020. The project coordinator and steering group
will have access to the complete dataset when available.
Statistics and data analysis
Sample size and power calculation
The sample size estimation was performed by the study
statistician for a stepped wedge cluster randomised de-
sign using STATA release 14 [34]. With 11 centres
(clusters) participating and an intra cluster correlation
(ICC) of 0.0026 a minimum sample size of 47,916 preg-
nant women (23,958 before change and 23,958 after
change of the new GDM criteria) have 90% statistical
power with a 5% significance level to detect an absolute
reduction in LGA by 1.5% on a population level (from
the existing 10 to 8.5%). ICC was estimated from the
variation in LGA incidence in year 2012 between
participating centres which varied between 7.7 and
13.3% (0.077–0.133). Assuming that the variation in
LGA incidence between centres follows a normal distri-
bution, the variation in LGA incidence were estimated
as mean 0.1067 and standard deviation (SD) 0.0164. The
coefficient of variation (CV) is 0.154 (SD divided by the
mean) and the CV can be expressed as an ICC.
The total estimated number of inclusions (=births)
during the inclusion period for the participating centres
is approximately 65,000. It is not possible to predict the
exact number of births during the study due to the dif-
ferences in sizes of the centres. Some incompleteness
(estimated 10%) of data on maternal characteristics
(mainly BMI) is expected. The calculation indicates that
there will be sufficient power for the main outcome
measure (LGA) even if 1–2 centres would drop out.
The proposed statistical analysis methods for stepped
wedge designs will be used including Generalized
Estimating Equation (GEE) models or mixed effect logistic
models to evaluate the primary outcome, LGA. Mixed ef-
fect logistic models will include centres as random effects,
which is the cluster and the randomisation unit in this de-
sign, and the intervention and time periods as fixed ef-
fects, or time as a random effect [35]. Adjustment for time
is to compensate for calendar time changes over time in
LGA incidences that are not due to the intervention chan-
ging from the old to new GDM criteria, but because of po-
tential temporal trends in LGA incidence.
As the randomisation is on the cluster level and not
on the participant level, we will adjust for important
prognostic predictors for LGA, such as chronic hyper-
tension, mother’s age, BMI, country of mother’s birth
and the mother’s smoking behaviour during pregnancy.
Stratification with interaction tests by prognostic factors
will be used to further investigate if the associations with
LGA between the two diagnostic criteria are heteroge-
neous and the new diagnostic criteria have an even lar-
ger impact in some subgroups according to risk factors.
Because of the stepped wedge study design, some rec-
ommended design-specific analyses will be conducted
such as stratification by time period to evaluate if the
intervention association with outcomes are homogenous
during the study time period, or heterogeneity within
centres between the two interventions. The secondary
adverse neonatal and maternal outcomes will be ana-
lysed using the same type of methods and considerations
as for the primary outcome. A sub-analysis will be con-
ducted comparing those with fasting glucose 5.1–6.9
mmol/L and/or 2-h glucose 8.5–8.9 mmol/L before and
after the switch in criteria.
Health economic evaluation
In a first health economic analysis, increased interven-
tion costs for new diagnostic criteria will be set against
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reduced healthcare costs during pregnancy and in con-
nection with childbirth. This cost analysis consists of 1)
estimation of standard cost of treatment of GDM, 2)
mother’s healthcare utilization during pregnancy and the
month after delivery and, 3) the infant’s health care
utilization the month after birth. Data are retrieved from
the SPR. Cost of health utilization is estimated based on
the Swedish national cost per Patient database.
In a second analysis, the mother’s quality of life during
pregnancy and after birth will also be included. It will be
expressed in quality adjusted life years (QALY) based on
a single item of self-rated health transformed to
preference-based values using a Swedish experience
based preference valuation [36]. Self-rated health data
during pregnancy and after birth is retrieved from the
SPR where it is already collected.
In a third analysis, long-term consequences will be
modelled. Differences in incidence of LGA will be mod-
elled on future health for the child and cost implications
based on best available evidence. In the same way, the
mother’s future health impact from intervention can be
modelled based on medical risk markers. Cost effective-
ness will be expressed in cost per QALY.
Discussion
To the best of our knowledge, the CDC4G study is the
first national SW-CRCT to evaluate the implementation
of the 2013 WHO criteria for GDM. There are a number
of non-randomised retrospective studies comparing out-
comes before and after the change in criteria. Small
studies in Spain and Taipei have shown improved preg-
nancy outcomes switching from the American Diabetes
Association (ADA) criteria to the IADPSG criteria on a
population basis [37–39]. A non-randomised retrospect-
ive study in the USA found no benefit in outcomes [40]
but substantial changes in clinical and obstetric care oc-
curred at the same time [41]. The few randomised trials
of treating GDM [12–14] have all studied different set-
tings and diagnostic criteria, and a randomised study of
the effect on outcomes by treatment on a population
level does not exist. Sweden has a public health care sys-
tem with almost 100% clinical attendance and public
health registries with high coverage. With the availability
of Swedish registers and possibility to link registers by
the personal identification number, this setting provides
a unique possibility to evaluate the impacts of the 2013
WHO criteria on pregnancy outcomes and long-term
health for both mother and child.
The IADPSG recommend universal screening [18],
however, in Sweden there has been a diverse approach
to screening as shown in Table 1. Screening criteria at
each centre did not change through the trial and should
not impact on the validity of the SW-RCT. Since univer-
sal screening with both fasting and 2-h values has not
been the routine; the existing screening approaches does
reduce the number of women who will have received
treatment for GDM, in spite of some hyperglycaemia.
Furthermore, in practice, many midwives find it difficult
to adhere fully to the plethora of screening criteria.
Therefore, any benefit (or harms) from GDM treatment
will be less than would have occurred with universal
screening.
SW-CRCT: strengths and limitations
The stepped wedge randomised controlled design is par-
ticularly beneficial when the intervention is likely to do
more good than harm and is mainly used to evaluate
routine implementation, as is the case for the CDC4G
trial. The design is practical where it is not possible to
deliver the intervention to all the participants at the
same time for logistical, practical or financial reasons.
The stepped wedge design is also appropriate for cost-
effectiveness analysis of an intervention on a population
basis (i.e. when changes across a whole population/ser-
vice occur), also making it suitable for the CD4G study.
Disadvantages of the stepped wedge design are diffi-
culties in blinding the participants and those delivering
the intervention since the step from control to interven-
tion is evident for both. It is also important to note that
the stepped wedge design is likely to lead to a longer
trial duration than a traditional parallel design, particu-
larly where effectiveness is measured immediately after
implementation. Since the implementation of the new
criteria is expected to do more good than harm and is
going to continue after the study period there are no real
disadvantages from the participant’s point of view. Step-
wedge trials can be impacted upon by wider secular
trends that can differ between the beginning and end of
the study period. In CDC4G, the design has included an
alignment, and run in, of all significant clinical policies
before the trial commenced, and a clear directive not to
introduce any service changes during the study period.
A major limitation in cluster randomised trials is the
need for larger numbers to overcome the ICC.
Ethics
Random allocation is performed at the cluster, not the
individual level, and prior informed consent to random-
isation is not feasible and will not be requested. This is
justifiable on the basis that this is a SNBHW policy dir-
ective and hence management of GDM is changing as a
result of the new national recommendation. It would be
unethical not to evaluate the impact of the move, and
the best approach for this evaluation is by conducting an
RCT. Women always have the right under Swedish Law
to change clinic and refuse any aspect of care.
As there is an a priori acceptance that the intervention
will do more good than harm [42], rather than belief of
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equipoise, it may be unethical to withhold the interven-
tion from a proportion of the participants, or to with-
draw the intervention as would occur in a cross-over
design.
Trial status
The study preparation period started during 2017 and
data collection 1st of January 2018. The first centre was
randomised to the 2013 WHO criteria 1st of February
2018 and the last 1st of November 2018. The study is
ongoing during 2018 and 2019, with first data collection
during 2020.
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